Harmony Biosciences Expects Higher Q2 Wakix Revenue; CFO Glenn Reicin Steps Down

MT Newswires Live07-16 21:06

Harmony Biosciences (HRMY) reported Thursday preliminary Q2 net product revenue for Wakix of around $261 million, up 30% year over year.

Analysts polled by FactSet expect $249.5 million.

The company reiterated its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion.

Analysts expect $1.01 billion.

In addition, the company said Chief Financial Officer Glenn Reicin stepped down to pursue other opportunities, effective immediately.

The company said it named Stephen Mollichella, currently the controller, as interim principal financial officer as it conducts its search for a permanent finance chief.

Harmony will report its Q2 financial results on Aug. 4.

Shares of the company were down more than 1% in premarket activity Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment